Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Value: focus on earnings, not yields

Fri, 12th Mar 2021 11:51

* STOXX 600 down 0.5%

* European tech falls, Nasdaq futures down 1.8%

* US 10 year hovering around 1.60%

* Dollar rises

March 12 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

VALUE: FOCUS ON EARNINGS, NOT YIELDS (1148 GMT)

Most of the market price action these days seems to be about
how U.S. Treasury yields impact the reflation trade versus
growth and tech.

Longer term though, Oddo and Barclays both issued strategy
notes stressing that actually, profit growth is what investors
should be focusing on when it comes to the revival of value and
cyclical stocks.

"Earnings are ultimately the fundamental driver of the
rotation, but are being overlooked given the price action in
rates", the Barclays equity team led by Emmanual Cau wrote.

"Relative EPS momentum is indeed picking up for the Value
part of the market, quite simply because these sectors’ earnings
were the most impacted by the pandemic and thus have the most to
regain as the economy reopens", the Barclays team added,
pointing at miners, energy groups and the banking sector.

At Oddo, strategist Sylvain Goyon says that the in-house
model shows that there's room for the Equity Risk Premium to
ease going forward and because of that, investors shouldn't
focus on the wrong indicators.

"It's more a retreat of expected EPS growth than a rise in
yields that markets should fear", Goyon writes, adding he's that
given the current trend, the outperformance of value is expected
to continue.

Here's a chart from the Barclays note showing there's still
quite a lot of potential upside in Europe when it comes to value
versus growth:

(Julien Ponthus)

*****

"IF THAT CREEPS BACK ABOVE 1.6%...." (1052 GMT)

That was a warning given yesterday by an equity trader about
the latest market price action on the Nasdaq.

The trader was referring to U.S. 10-year Treasury yields
which look like all you need to watch these days to guess where
the Nasdaq is heading to.

When yields rise to 1.6%, sell Nasdaq!

When they touch 1.5% or lower, buy!

And guess what? This morning the U.S. yields were hovering
around 1.60% and Nasdaq futures, surely enough, are falling,
currently down 1.8%.

That's pretty much been the narrative since late February.

Why? Investors typically are willing to pay more for
near-term growth when rates rise as cyclicals tend to do well in
the early days of economic boom.

And on the contrary, they want to pay less for long-term
growth in this phase.

Okay but what's a long-duration stock?

Goldman has a very simple definition: stocks with strong
long-term growth prospects, in particular those that are not
cash flow positive currently, have the longest equity duration.

Some of the names in Goldman's long duration basket: Peloton
Interactive, Beyond Meat, Moderna, Lyft, Fastly, Zoom. All these
stocks were winners in 2020 when rates were near record lows and
have pulled back quite a bit in the recent days.

With those names it's clear that tech stocks have the
longest equity duration. Hence, the tech heavy Nasdaq 100 has
taken a beating in the past few weeks.

Here's a chart showing strong correlation with yields:

(Thyagaraju Adinarayan)

*****

EARNINGS MOMENTUM FOR THE S&P (1015 GMT)

The U.S. are expected to offset the adverse impact of rising
yields with a strong recovery coupled with expansion of
earnings, which is the main equity key driver.

“Much better than expected earnings should drive further S&P
500 upside through 2021,” UBS analysts say.

"We raise our S&P 500 price target for year end to 4250,
from 4100, on higher forecasted EPS of $188 for 2021 and $218
for 2022", they add.

While the Fed's policy will be crucial as higher rates have
an impact on stock valuations, politics also have to be closely
monitored. More corporate and capital gains taxes coupled with
greater regulation would reduce UBS estimates by 12%.

(Stefano Rebaudo)

*****

EUROPE ON THE BACKFOOT (0837 GMT)

A cocktail of reasons for the pullback in Europe this
morning, despite strong sessions in U.S. and Asia overnight. The
Stoxx 600 index is however comfortably poised to record a gain
for the week.

Concerns about the vaccination campaign, with AstraZeneca
further cutting its supply forecast are dampening risk
sentiment.

Then we have yields on the rise above 1.6% in early London
trading and China warning the United States to stop interfering
in its affairs, including Hong Kong.

The Stoxx 600 index is down 0.3%, with Tech stocks leading
losses down 1.2%, inline with Nasdaq futures.

Shares in online investor Prosus are down 4.4%,
after China's watchdog imposed administrative penalties on 12
companies including Internet giants Tencent and Baidu for
violating anti-monopoly law in 10 deals.

Bank stocks are in positive territory after
yesterday’s strong post-ECB selloff.

Burberry is the best performer of Stoxx 600, up 7%,
after the company raised its outlook.

(Stefano Rebaudo)

*****

TROUBLE RETURNS (0811 GMT)

U.S. 10-year Treasury yields are on track to rise for the
seventh week straight. But a measure of calm that had returned
in recent days seems to have dissipated on Friday as yields are
making their way back towards recent one-year highs above 1.6%.

Euro zone yields too are higher this morning, though to a
lesser extent, still benefiting from the ECB's promise to
accelerate emergency money-printing.

That in turn is putting the dampener on stock markets --
world stocks rose three days in a row as U.S. yields pulled back
but are now turning tail -- Nasdaq futures are down 1%. Futures
for the S&P500 and for European stocks are also weaker, albeit
to a lesser degree.

So what's going on? Jobs data on Thursday indicated the U.S.
economy is well on the road to recovery while President Joe
Biden signed into law a $1.9 trillion COVID-19 relief bill and
a 30-year Treasury auction had a mixed outcome.

That was partly down to dealers offloading Treasuries to
hedge a corporate bond deal from Verizon, it nonetheless
continues to suggest persistent uncertainty about appetite for
U.S. government debt.

And as the risk sentiment sours going into the weekend, the
dollar has risen off one-week low against its rivals, slamming
currencies such as the euro and Aussie dollar almost half a
percent lower. An index of emerging market currencies which on
Thursday posted its biggest rise since early-January has fallen
back.

But it's not all bad news. The Nasdaq, despite a recent
recovery, remains well behind the Dow 30, S&P and Russell 2000
indexes which have hit records -- clearly investors, seeing
economic recovery on the horizon, are piling into old economy
stocks such as banks and energy.

Key developments that should provide more direction to markets
on Friday:
-Britain's economy shrank by 2.9% in January from December
-Brent oil prices ease but stay near $70 a barrel
-British luxury group Burberry raises outlook after strong
bounceback in sales;
-Apple's market value could breach $3 trillion if the iPhone
maker successfully makes Apple Car, Citi says,
-Euro area industrial production
-Canada employment report

(Saikat Chatterjee)

*****

EUROPEAN FUTURES TAKE A BREATHER (0633 GMT)

European stock futures are pointing to a session flat or
slightly in the red, as equities seem keen on taking a breather
after a rally which drove the Stoxx 600 index close to
pre-pandemic levels.

Germany’s Dax has been hitting fresh record highs since the
start of the week and many Europe’s benchmark sectoral indexes
are at their highest levels or close to them.

The bigger picture remains favourable to risk sentiment
after the ECB announced an increase of PEPP buying pace to keep
a lid on borrowing costs, while subsiding inflation fears
boosted Wall Street and Asian stocks overnight.

(Stefano Rebaudo)

*****

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.